Skip to content

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe

Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe - EU-CERT-ICD study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON41346
Enrollment
88
Registered
2014-07-09
Start date
2015-06-29
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden cardiac death

Interventions

None listed

Sponsors

University Medical Center Göttingen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Ischaemic or non-ischaemic (dilated) cardiomyopathy and recommendation for primary prophylactic ICD treatment following current international treatment guidelines -Age * 18 years -Written informed consent -If ICD implantation is planned, enrolment and study baseline testing needs to be completed before de-novo ICD implantation

Exclusion criteria

Exclusion criteria: -Persistent or permanent atrial fibrillation in the baseline ECG recordings in no more than 15% of such patients at a given time have been enrolled, thus atrial fibrillation is an exclusion criteria only if this percentage has been surpassed in the overall enrolled patient population -Indication for other than above mentioned primary prophylactic ICD treatment -Indication for secondary prophylactic ICD treatment -Indication or candidate for cardiac resynchronisation therapy, i.e.: (1) QRS duration of *135 ms, left bundle branch block QRS morphology, and an LVEF *35% or (2) QRS duration *150 ms, irrespective of QRS morphology, and an EF *35% -QRS duration of 120-130 msec, left bundle branch block QRS morphology, and an EF *35%, if the investigator deems cardiac reysnchronisation therapy indicated -AV block II°-III° at resting heart rates -Implanted pacemaker -Unstable cardiac disease such as decompensated heart failure (NYHA functional class IV) or acute coronary syndrome -Participation in other clinical trials which exclude enrolment in other trials

Design outcomes

Primary

MeasureTime frame
Primary study endpoint is all-cause mortality. Co-primary endpoint is the time to first appropriate shock as defined as an ICD high voltage therapy delivered appropriately for malignant ventricular arrhythmia (per judgement of the investigator and the endpoint committee).

Secondary

MeasureTime frame
-ICD Electrical Shock Endpoints (including Inappropriate ICD Shock) -Mortality Endpoints (SCD, Cardiac Death and Non-Cardiac Death) -other Clinical Endpoints: Arrhythmogenic Syncope, Resuscitation, Any ICD Shock, Atrial Fibrillation -Quality of Life -Device Revision/Replacement -Costs and Cost-effectiveness

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)